help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by O'Brien, R. C.
Right arrow Articles by Jerums, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by O'Brien, R. C.
Right arrow Articles by Jerums, G.

Journal of Clinical Endocrinology & Metabolism, Vol 72, 1008-1013, Copyright © 1991 by Endocrine Society


ARTICLES

Comparison of sequential cyproterone acetate/estrogen versus spironolactone/oral contraceptive in the treatment of hirsutism

RC O'Brien, ME Cooper, RM Murray, E Seeman, AK Thomas and G Jerums
Department of Endocrinology, Austin Hospital, Heidelberg, Victoria, Australia.

The effects of the antiandrogen drugs cyproterone acetate (CPA) and spironolactone on hair growth and androgen levels were compared in a randomized study of 48 hirsute women. Twenty six subjects completed 6 months of therapy with 100 mg/day CPA and 19 subjects completed 6 months of 100 mg/day spironolactone. All except 10 subjects received concomitant estrogen therapy. Measured objectively, total hair diameter fell by 17.1% with spironolactone (P less than 0.001), and by 16.8% with CPA (P less than 0.001). The diameter of the hair medulla fell by 17.8% with spironolactone (P less than 0.01), and by 31.7% with CPA (P less than 0.001). There was no difference between the drugs in their effect on hair diameter. Plasma testosterone levels also fell significantly with both drugs. As a subjective assessment of treatment efficacy, the frequency with which subjects performed cosmetic measures was recorded. This fell by 38% with spironolactone and by 44.7% with CPA (P less than 0.001 both drugs), and again there was no difference between the drugs. Side effects caused cessation of treatment in one subject taking CPA and two subjects taking spironolactone, and milder side effects were noted in two further subjects from each treatment group. We conclude that spironolactone and CPA, in the dosages used in this study, are effective and well tolerated agents for the treatment of hirsutism, and that neither drug demonstrates a particular advantage over the other.


This article has been cited by other articles:


Home page
Obstet GynecolHome page
R. Azziz
The Evaluation and Management of Hirsutism
Obstet. Gynecol., May 1, 2003; 101(5): 995 - 1007.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
R. Azziz, E. Carmina, and M. E. Sawaya
Idiopathic Hirsutism
Endocr. Rev., August 1, 2000; 21(4): 347 - 362.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
D. Deplewski and R. L. Rosenfield
Role of Hormones in Pilosebaceous Unit Development
Endocr. Rev., August 1, 2000; 21(4): 363 - 392.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
P. Moghetti, F. Tosi, A. Tosti, C. Negri, C. Misciali, F. Perrone, M. Caputo, M. Muggeo, and R. Castello
Comparison of Spironolactone, Flutamide, and Finasteride Efficacy in the Treatment of Hirsutism: A Randomized, Double Blind, Placebo-Controlled Trial
J. Clin. Endocrinol. Metab., January 1, 2000; 85(1): 89 - 94.
[Abstract] [Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1991 by The Endocrine Society